Revolution Medicines

Redwood City, California biotechnology company incorporated in 2014 and focused on RAS-addicted cancers; Rasonque (daraxonrasib) is its first FDA-approved medicine, targeting multiple RAS mutant forms rather than one.

revmed.com

2 stories

Regulatory News has published 2 stories about Revolution Medicines between 26 August 2026 and 17 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 17 October 2026.

This page is generated from Regulatory News’ editorial coverage of Revolution Medicines. It is not an advertisement.

Products in our coverage

RASONQUEdaraxonrasib

Our coverage

2 stories, newest first.

A researcher in a lab coat and face shield uses a pipette with blue reagent, standing in for small-molecule drug research

For Physicians EMA Recommends First RAS Inhibitor for Pancreatic Cancer Oct 17, 20269 min read Read the story

The dome of the California State Capitol building against a deep blue sky, with a tree visible at the frame's edge

Drugs & Biologics FDA Approves Rasonque, First RAS-Targeted Cancer Drug Aug 26, 20265 min read Read the story

All companies